Back to Search
Start Over
Prediction of acute toxicity grade ≥ 3 in patients with locally advanced non-small-cell lung cancer receiving intensity modulated radiotherapy and concurrent low-dose Cisplatin.
- Source :
-
Clinical lung cancer [Clin Lung Cancer] 2013 Sep; Vol. 14 (5), pp. 541-8. Date of Electronic Publication: 2013 Jul 05. - Publication Year :
- 2013
-
Abstract
- Background: Intensity modulated radiotherapy (IMRT) is increasingly used with concurrent chemotherapy but toxicity data are not well investigated. We correlated clinical and dosimetric parameters with acute toxicity grade ≥ 3 in patients with locally advanced NSCLC treated with IMRT and concurrent low-dose cisplatin.<br />Patients and Methods: We analyzed age, PS, comorbidities, gross tumor volume, and the volume of the esophagus irradiated with 50 Gy (V50oes) in relation with acute toxicity. The mean lung dose (MLD) and pulmonary toxicity was described. Treatment consisted of 24 × 2, 75 Gy, and daily cisplatin 6 mg/m². Patients with an MLD ≥ 20 Gy or a PS > 2 were excluded from CCRT. Toxicity was prospectively scored using the Common Toxicity Criteria for adverse events version 3.0. The Charlson Comorbidity Index (CCI) was applied for scoring comorbidities. Multivariable logistic regressions for toxicity and survival estimates (Kaplan-Meier) were used for evaluation.<br />Results: From 2008 to 2011, 188 patients received standard CCRT. In 35% of the patients, acute toxicity grade ≥ 3 was reported. Grade 5 toxicity was scored in 1% of the patients. V50oes (odds ratio [OR], 1.33 per 10% increase; P = .01) and PS ≥ 2 (OR, 3.45; P = .07) were significantly correlated with acute toxicity ≥ grade 3. No differences in toxicity were observed between age groups (< 70 and ≥ 70; P = .26), and those with a CCI score < 5 and ≥ 5, and acute severe toxicity (P = .36). Grade ≥ 3 pulmonary toxicity was seen in 7%. The 1- and 2-year overall survival in stage III disease were 78% and 52%, respectively. Patients with a poor PS or a high CCI score had similar survival outcomes.<br />Conclusion: Concurrent low-dose cisplatin using IMRT is effective in a large cohort of consecutive patients with NSCLC and life threatening toxicity is rare (1%). PS ≥ 2 and V50oes are correlated with acute toxicity grade ≥ 3.<br /> (Copyright © 2013 Elsevier Inc. All rights reserved.)
- Subjects :
- Adenocarcinoma mortality
Adenocarcinoma pathology
Adult
Aged
Aged, 80 and over
Antineoplastic Agents adverse effects
Carcinoma, Non-Small-Cell Lung mortality
Carcinoma, Non-Small-Cell Lung pathology
Carcinoma, Squamous Cell mortality
Carcinoma, Squamous Cell pathology
Comorbidity
Dose-Response Relationship, Drug
Esophagus drug effects
Esophagus radiation effects
Female
Follow-Up Studies
Humans
Lung Neoplasms mortality
Lung Neoplasms pathology
Male
Middle Aged
Neoplasm Staging
Prognosis
Prospective Studies
Survival Rate
Adenocarcinoma therapy
Carcinoma, Non-Small-Cell Lung therapy
Carcinoma, Squamous Cell therapy
Chemoradiotherapy adverse effects
Cisplatin adverse effects
Lung Neoplasms therapy
Radiotherapy, Intensity-Modulated adverse effects
Subjects
Details
- Language :
- English
- ISSN :
- 1938-0690
- Volume :
- 14
- Issue :
- 5
- Database :
- MEDLINE
- Journal :
- Clinical lung cancer
- Publication Type :
- Academic Journal
- Accession number :
- 23835165
- Full Text :
- https://doi.org/10.1016/j.cllc.2013.04.001